Category Archives: Neuroscience

Neuroscience

Cerevel Therapeutics to Participate at Upcoming Virtual Investor Conferences – Yahoo Finance

CAMBRIDGE, Mass., Nov. 01, 2021 (GLOBE NEWSWIRE) -- Cerevel Therapeutics (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, announced that it will participate in four upcoming virtual investor conferences during the months of November and December.

Event:

Virtual Guggenheim 3rd Annual Neuro/Immunology Conference

Date:

November 15, 2021

Format:

One-on-one meetings with members of the investor relations team

Event:

Stifel 2021 Virtual Healthcare Conference

Date:

November 16, 2021

Format:

Fireside chat with Chairperson and CEO Tony Coles, M.D.

One-on-one meetings with members of the management team

Time:

8:40 a.m. ET

Event:

Jefferies London Healthcare Conference

Date:

November 18, 2021

Format:

One-on-one meetings with members of the management team

Event:

Evercore ISI HealthCONx Conference

Date:

December 1, 2021

Format:

Fireside chat with Chairperson and CEO Tony Coles, M.D.

One-on-one meetings with members of the management team

Time:

9:40 a.m. ET

Live audio webcasts of the virtual conference fireside chats can be accessed on the investor relations section of the Cerevel Therapeutics website here. Replays will also be available in the same section of the companys website.

About Cerevel TherapeuticsCerevel Therapeutics is dedicated to unraveling the mysteries of the brain to treat neuroscience diseases. The company is tackling diseases with a targeted approach to neuroscience that combines expertise in neurocircuitry with a focus on receptor selectivity. Cerevel Therapeutics has a diversified pipeline comprising five clinical-stage investigational therapies and several pre-clinical compounds with the potential to treat a range of neuroscience diseases, including Parkinsons, epilepsy, schizophrenia, and substance use disorder. Headquartered in Cambridge, Mass., Cerevel Therapeutics is advancing its current research and development programs while exploring new modalities through internal research efforts, external collaborations, or potential acquisitions. For more information, visit http://www.cerevel.com.

Story continues

Special Note Regarding Forward-Looking StatementsThis press release contains forward-looking statements that are based on managements beliefs and assumptions and on information currently available to management. In some cases, you can identify forward-looking statements by the following words: may, will, could, would, should, expect, intend, plan, anticipate, believe, estimate, predict, project, potential, continue, ongoing or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. These statements involve risks, uncertainties and other factors that may cause actual results, levels of activity, performance, or achievements to be materially different from the information expressed or implied by these forward-looking statements. Although we believe that we have a reasonable basis for each forward-looking statement contained in this press release, we caution you that these statements are based on a combination of facts and factors currently known by us and our projections of the future, about which we cannot be certain. Forward-looking statements in this press release include, but are not limited to, statements about our upcoming virtual investor conference participation and the potential attributes and benefits of our product candidates. We cannot assure you that the forward-looking statements in this press release will prove to be accurate. Furthermore, if the forward-looking statements prove to be inaccurate, the inaccuracy may be material. Actual performance and results may differ materially from those projected or suggested in the forward-looking statements due to various risks and uncertainties, including, among others: clinical trial results may not be favorable; uncertainties inherent in the product development process (including with respect to the timing of results and whether such results will be predictive of future results); the impact of COVID-19 on the timing, progress and results of ongoing or planned clinical trials; other impacts of COVID-19, including operational disruptions or delays or to our ability to raise additional capital; whether and when, if at all, our product candidates will receive approval from the FDA or other regulatory authorities, and for which, if any, indications; competition from other biotechnology companies; uncertainties regarding intellectual property protection; and other risks identified in our SEC filings, including those under the heading Risk Factors in our Quarterly Report on Form 10-Q filed with the SEC on August 11, 2021 and our subsequent SEC filings. In light of the significant uncertainties in these forward-looking statements, you should not regard these statements as a representation or warranty by us or any other person that we will achieve our objectives and plans in any specified time frame, or at all. The forward-looking statements in this press release represent our views as of the date of this press release. We anticipate that subsequent events and developments will cause our views to change. However, while we may elect to update these forward-looking statements at some point in the future, we have no current intention of doing so except to the extent required by applicable law. You should, therefore, not rely on these forward-looking statements as representing our views as of any date subsequent to the date of this press release.

Media Contact:Kate ContrerasReal Chemistrykcontreras@realchemistry.com

Investor Contact:Matthew CalistriCerevel Therapeuticsmatthew.calistri@cerevel.com

See the original post here:
Cerevel Therapeutics to Participate at Upcoming Virtual Investor Conferences - Yahoo Finance

Neuroscience

$1.7M MPower Grant to Support UMCP, UMB Health Research Collaborations – Maryland Today

A new grant will provide $1.725 million over three years to support research collaborations between the University of Maryland, College Park (UMCP) and the University of Maryland, Baltimore (UMB) aiming to improve health care.

The grant from the University of Maryland Strategic Partnership, MPowering the State, and accompanying cooperative agreement will allow researchers across the College Park campus to partner with UMBs Institute for Clinical and Translational Research (ICTR). The institute focuses on putting health-related scientific findings to work, and offers expert patient- and community-centered services; biostatistical support for study design, implementation, and interpretation; and pre- and postdoctoral training awards.

The MPower award will help researchers access resources for clinical training, reduce barriers to patient recruitment and open new avenues for human-subject research at UMCP.

The effort is co-led by Dr. Stephen N. Davis, the Dr. Theodore E. Woodward Chair of the Department of Medicine at the University of Maryland School of Medicine and director of the ICTR in Baltimore, and Professor Elizabeth Quinlan, the Clark Leadership Chair in Neuroscience, Department of Biology, and director of the Brain and Behavior Instituteat UMCP.

Access to ICTR resources will enable the translation of high-impact research from the laboratory to the clinic, said Quinlan. The MPower funding to establish this strategic partnership reflects the commitment to training and will accelerate new bi-campus collaborations.

The ICTR, supported by funding from the National Institutes of Health, was established at UMB in 2017 as a universitywide, interdisciplinary hub with a mission to turn basic research findings into novel technologies and practices with communitywide impact. Through the MPower funding, College Park faculty researchers in the life sciences, public health, neuroscience, bioengineering and other disciplines related to clinical and translational research are now eligible to submit proposals for services provided by the ICTR. In addition, College Park students, postdocs and faculty will be invited to compete for career development and mentoring funding. College Park faculty are also eligible to apply for the ICTR Accelerated Translational Incubator Pilot voucher program.

To further strengthen this partnership, MPower funds will continue to develop UMBs bioinformatic infrastructure, which applies computational analysis to biological and health information.

These resources will scale up the ICTRs informatics capabilities and help generate compelling data that demonstrate the effective and seamless clinical research partnership of the two campuses, said Davis. The MPower agreement will create a clinical research network across Maryland that benefits both the population of the state and faculty in Baltimore and College Park.

The MPower announcement follows the news earlier this year that the University of Maryland achieved its highest-ever ranking in the National Science Foundations Higher Education Research and Development survey, as a result of Baltimore and College Park research enterprise being linked together for the first time.

"This will create exciting new opportunities for our researchers to collaborate and deepen the impact of our combined research productivity across our College Park and Baltimore campuses," said Interim Vice President for Research Amitabh Varshney. "For College Park researchers new to the ICTR, the program will provide a high-quality environment for clinical and translational research and will foster innovation in research methods and training."

Read the original here:
$1.7M MPower Grant to Support UMCP, UMB Health Research Collaborations - Maryland Today

Neuroscience

Exicure to Present at Upcoming Scientific Conferences – Business Wire

CHICAGO & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Exicure, Inc. (NASDAQ: XCUR), a pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid (SNA) technology, today announced presentations at the following scientific conferences during the month of November:

TIDES EUTitle: "Development of Spherical Nucleic Acids Targeting SCN9A For the Treatment of Neuropathic Pain"Presented by: Bart Anderson, Senior Director, R&DDate: November 16, 2021Time: 8:45am CET / 1:45am U.S. CST

Neuroscience 2021 (The Society for Neuroscience)Poster 1: "Spherical Nucleic Acids Targeting FXN Induce Frataxin Expression in Models of Friedreichs Ataxia"Presented by: Grant Corbett, Group Lead, NeurosciencePoster 2: "Biodistribution of Spherical Nucleic Acids in the Mouse CNS Following ICV, ICM and IT Delivery"Presented by: Lauren Moore, Senior Scientist, NeuroscienceNovember 8-11, 2021

About Exicure, Inc.

Exicure, Inc. is a clinical-stage biotechnology company developing therapeutics for neurology, immuno-oncology, inflammatory diseases and other genetic disorders based on its proprietary Spherical Nucleic Acid, or SNA technology. Exicure believes that its proprietary SNA architecture has distinct chemical and biological properties that may provide advantages over other nucleic acid therapeutics and may have therapeutic potential to target diseases not typically addressed with other nucleic acid therapeutics. Exicure is in preclinical development of XCUR-FXN, a lipid-nanoparticle SNAbased therapeutic candidate, for the intrathecal treatment of Friedreichs ataxia (FA). Exicures therapeutic candidate cavrotolimod (AST-008) is in a Phase 1b/2 clinical trial in patients with advanced solid tumors. Exicure is based in Chicago, IL and in Cambridge, MA. http://www.exicuretx.com

See the article here:
Exicure to Present at Upcoming Scientific Conferences - Business Wire

Neuroscience

Female-Led Team Investigates Increased Alzheimer’s Risk in Women – Duke Today

This MRI scan of a mouse brain, enhanced with manganese, shows 332 regions of the brain. Quantifying volumes and texture helps reveal vulnerable regions and circuits.

By Dana Adcock 22

For Duke faculty members Christina Williams and Alexandra Badea, their research on Alzheimers disease feels deeply personal.

I have seen what Alzheimers is like in the family, so I think Im particularly fortunate to be able to contribute to Alzheimers research, said Badea, an associate professor in radiology and neurology. Even if this is just pushing the field forwards by half of a millimeter, Im very grateful for this chance.

Williams, who is a professor of psychology and neuroscience, agreed. Ive seen the effects of Alzheimers on real people, people I love and care about, she noted. Being able to actually do something, and as Alex said, moving the field forward, is something that we all feel anxious to do. Any little contribution we can make is one that we think is valuable.

The two researchers combined expertise in neuroscience and radiology has paired well together throughout the years.

Alex and I came together in large part because were both interested in memory and in Alzheimers disease, said Williams. Alex is particularly interested in using imaging technology to look at the sizes of different things in the brains of mice, and also levels of activity and connectivity of brain circuits. She looks at the circuit and system level, whereas the work in my lab tends to look more specifically at individual cell types that are affected by Alzheimers disease in particular brain regions.

Immunohistochemistry stains of Alzheimers plaque and microglia in mouse brains. Microglia are important for maintaining a healthy central nervous system.

Williams and Badeas overarching goal is to combine their techniques to get at what is changing in the brain from Alzheimers. Along with that, theyre interested in how environmental factors, such as estrogen loss and exercise, alter the course of the disease.

For the past five years, they have led Bass Connections teams to involve undergraduate and graduate students in tackling this issue. Their current team, Alzheimers Disease: Exercise Therapy and Brain Networks, is focusing on the disease in women.

One of the things thats lesser known about Alzheimers disease is that women are considerably more vulnerable.

Two thirds of the patients with Alzheimers are women, and the disease progresses more rapidly in women, said Williams. Some of the symptoms are a little bit different in women than in men. The question of why women are more vulnerable is one of the questions that were interested in asking and trying to get answers to.

The team uses mouse models to examine the impact of exercise and estrogen loss on Alzheimers disease. Some of the mouse models demonstrate familial Alzheimer's, which is the early onset type and genetically determined. Others mimic the later onset type, which is more common but has fewer known causes. They utilize technologies like fMRI scans and immunohistochemistry to visualize the progression of the disease in the mices brains.

Ph.D. candidate Janai Williams

Psychology & Neuroscience Ph.D. candidate Janai Williams serves as the teams project manager. Joining the project a year after its inception, she embraced the chance to learn from continuing members.

I was able to build my knowledge from the undergraduates who are brilliant and have such great skills, said Williams. Once I got a stronghold of the project, the diverse knowledge and thought helped me build on my own questions within this project [and bring them into] what Im planning to do for my future dissertation project and what Ive presented for my thesis.

Undergraduate Divya Reddy

Undergraduates work in subteams, tackling different aspects of the project. My role in the project lies more within the exercise therapy aspect of the team, Divya Reddy (Biology 23) explained. Her subteam is using mouse models to look at the effects of chronic exercise as opposed to sedentary mice or non-chronic exercise.

Meanwhile, Eileen Wen(24) is using immunohistochemistry to test whether the teams menopause models actually are working effectively and whether they have categorized the mice into the right cycling or non-cycling female group.

Undergraduate Eileen Wen

The project team includes eight other undergraduate members: Akhil Bedapudi, Nikhil Gadiraju, Melinda Guo, Kyra Hoskin, Jasmine King, Pradnesh Kolluru, Anna MacFarlane and Isabella Pansini.

Despite focusing on different research areas, students say they still feel connected to the rest of the team. With Bass Connections, the whole goal is to try and make sure that you always feel supported and feel like youre in the know with everyone elses project, said Pansini (Neuroscience 23). It becomes easier to integrate everyones information and everyones project together because ultimately we are working toward the same goal.

The team plans to analyze and compare brain imaging data from mouse models of Alzheimers disease to brain neuropathology, behavioral data and databases of human brain imaging from Alzheimers patients. Team members will contribute to publications and posters and present these to the research community and clinical consumers. They also hope to create a website to share their findings with the public.

Duke University senior Dana Adcock is a Bass Connections communications assistant who is majoring in Environmental Sciences & Policy.

See more here:
Female-Led Team Investigates Increased Alzheimer's Risk in Women - Duke Today

Neuroscience

Neuroscience Antibodies and Assays Market 2021 Outlook, Demand, Regional Analysis, Industry Value Chain | Operating Vendors: Thermo Fisher, Abcam,…

The latest research report on the Global Neuroscience Antibodies and Assays Market provides the cumulative study on the COVID-19 outbreak to provide the latest information on the key features of the Neuroscience Antibodies and Assays market. This intelligence report contains investigations based on current scenarios, historical records and future forecasts. The report contains various market forecasts related to market size, revenue, production, CAGR, consumption, gross margin in the form of charts, graphs, pie charts, tables and more. While emphasizing the main driving and restraining forces in this market, the report also offers a comprehensive study of future trends and developments in the market. It also examines the role of the major market players involved in the industry, including their business overview, financial summary and SWOT analysis. It provides a 360-degree overview of the industries competitive landscape. Neuroscience Antibodies and Assays Market shows steady growth and CAGR is expected to improve during the forecast period.

The Global Neuroscience Antibodies and Assays Market Report gives you in-depth information, industry knowledge, market forecast and analysis. The global Neuroscience Antibodies and Assays industry report also clarifies financial risks and environmental compliance. The Global Neuroscience Antibodies and Assays Market Report helps industry enthusiasts including investors and decision makers to make reliable capital investments, develop strategies, optimize their business portfolio, succeed in innovation and work safely and sustainably.

Get FREE Sample copy of this Report with Graphs and Charts at:https://reportsglobe.com/download-sample/?rid=353214

The segmentation chapters enable readers to understand aspects of the market such as its products, available technology and applications. These chapters are written to describe their development over the years and the course they are likely to take in the coming years. The research report also provides detailed information on new trends that may define the development of these segments in the coming years.

Neuroscience Antibodies and Assays Market Segmentation:

Neuroscience Antibodies and Assays Market, By Application (2016-2027)

Neuroscience Antibodies and Assays Market, By Product (2016-2027)

Major Players Operating in the Neuroscience Antibodies and Assays Market:

Company Profiles This is a very important section of the report that contains accurate and detailed profiles for the major players in the global Neuroscience Antibodies and Assays market. It provides information on the main business, markets, gross margin, revenue, price, production and other factors that define the market development of the players studied in the Neuroscience Antibodies and Assays market report.

Global Neuroscience Antibodies and Assays Market: Regional Segments

The different section on regional segmentation gives the regional aspects of the worldwide Neuroscience Antibodies and Assays market. This chapter describes the regulatory structure that is likely to impact the complete market. It highlights the political landscape in the market and predicts its influence on the Neuroscience Antibodies and Assays market globally.

Get up to 50% discount on this report at:https://reportsglobe.com/ask-for-discount/?rid=353214

The Study Objectives are:

This report includes the estimation of market size for value (million USD) and volume (K Units). Both top-down and bottom-up approaches have been used to estimate and validate the market size of Neuroscience Antibodies and Assays market, to estimate the size of various other dependent submarkets in the overall market. Key players in the market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All percentage shares, splits, and breakdowns have been determined using secondary sources and verified primary sources.

Some Major Points from Table of Contents:

Chapter 1. Research Methodology & Data Sources

Chapter 2. Executive Summary

Chapter 3. Neuroscience Antibodies and Assays Market: Industry Analysis

Chapter 4. Neuroscience Antibodies and Assays Market: Product Insights

Chapter 5. Neuroscience Antibodies and Assays Market: Application Insights

Chapter 6. Neuroscience Antibodies and Assays Market: Regional Insights

Chapter 7. Neuroscience Antibodies and Assays Market: Competitive Landscape

Ask your queries regarding customization at: https://reportsglobe.com/need-customization/?rid=353214

How Reports Globe is different than other Market Research Providers:

The inception of Reports Globe has been backed by providing clients with a holistic view of market conditions and future possibilities/opportunities to reap maximum profits out of their businesses and assist in decision making. Our team of in-house analysts and consultants works tirelessly to understand your needs and suggest the best possible solutions to fulfill your research requirements.

Our team at Reports Globe follows a rigorous process of data validation, which allows us to publish reports from publishers with minimum or no deviations. Reports Globe collects, segregates, and publishes more than 500 reports annually that cater to products and services across numerous domains.

Contact us:

Mr. Mark Willams

Account Manager

US: +1-970-672-0390

Email: [emailprotected]

Website: Reportsglobe.com

Continue reading here:
Neuroscience Antibodies and Assays Market 2021 Outlook, Demand, Regional Analysis, Industry Value Chain | Operating Vendors: Thermo Fisher, Abcam,...

Neuroscience

Neuroscience Market:Industry Analysis and Forecast 2021-2027| Key Players Doric Lenses . GE Healthcare , Siemens Healthineers , Laserglow Technologies…

Neuroscience Marketis the study of the nervous system and it is concerned with assessing and imaging brain function. Neuroscience is a comprehensive term that refers to the study of the nervous systems molecular, cellular, developmental, structural, functional, evolutionary, computing, psychological, and medicinal components.

Maximize Market Research has published a comprehensive research and analysis of theNeuroscience Market, which identifies new developments in theNeuroscience Marketand gives business insights to organisations. This research assists manufacturers, suppliers, and investors, as well as CEOs, in identifying opportunities and business optimization techniques for increasing their value in the worldwideNeuroscience Market. Provides critical information for well-known organisations that are among the best performers. The research covers present and new markets in depth, as well as an assessment of competitiveness in shifting market circumstances.

List of Key players: Following are the number of key players studied to understand theNeuroscience Market:

Doric Lenses GE Healthcare Siemens Healthineers Laserglow Technologies Mightex Systems NEURALINK Kernel BrainCo, Inc. MindMaze Paradromics NeuroPro NeuroSky EMOTIV Cercare Medical A/S Plexon, Inc. Noldus Information Technology bv Femtonics Ltd. Neuralynx

Enquiry before buying this premium Report:

Request Sample

This study estimates the size of theNeuroscience Marketin terms of both value and volume. It includes a thorough examination of the markets major drivers, restraints, and opportunities. Through the Porters five forces analysis, the study examines the major elements that contribute to the growth of theNeuroscience Market. Furthermore, the market participants have been profiled, with a particular emphasis on their product offers.

The research also includes data in the form of statistics, facts, and figures, as well as contact information and sales contact information for the global markets leading players. There is a full picture of the global Silk industrys competitive landscape, with all information gathered and deepened with the SWOT analysis. Opportunities for possible industrial expansion have been identified, as have the competitive threats associated.

The report also discusses critical industry niches such as items or services supplied, downstream fields, end-user customers, historical data figures for revenue and sales, market background, and more. To acquire a better understanding of the companies, globalNeuroscience Market-leading main players have been profiled. It offers specific expansions to a variety of high-level industries operating around the globe. The section also includes useful information such as an overview of the firm and its market share, company biographies, and some significant methods used by key companies to build their businesses.

The introduction of new goods and the research involved in the development of innovative products is one of the primary components that is likely to have an impact on theNeuroscience Market.The study provides information on the sales and market growth of various markets on a regional and national scale. This report is to provide a market analysis in terms of growth patterns, prospects, and market players contributions to market development. The research also examines market demand growth estimates for products and services.

OBJECTIVES OF THE STUDY

Our Research Methodology:

This research study involves the use of extensive secondary sources such as encyclopedia, directories, and databases to identify and collect information useful for this technical, market-oriented, and commercial study of theNeuroscience Market. Primary sources that include selected experts from related industries and selected suppliers have been interviewed to obtain and verify important information as well as to assess future prospects. As a part of the secondary research process, various sources have been referred to for identifying and collecting information for this study. Secondary sources include annual reports, press releases, and investor presentations of companies; white papers; certified publications, articles from recognized authors; and gold & silver standard websites.

Browse Complete Neuroscience Market Report details and List Of Figures Here:

Neuroscience Market: Global Industry Analysis And Forecast (2022-2029)

About Us.:

Maximize Market Research has served esteemed clients including Yamaha, Boeing, Sensata, Etnyre, Canada, ALCOR M&A, Microsoft, Harman, and other 200 MNCs worldwide. The Company provides B2B and B2C market research on 5000 high growth emerging technologies & opportunities in Transportation, Chemical, Healthcare, Pharmaceuticals, Electronics & Communications, Internet of Things, Food and Beverages, Aerospace and Defense and other manufacturing sectors.We, at Maximize Market Research, are a strong unified team of industry specialists and analysts across sectors to ensure entire Industry ecosystem is taken in perspective, factoring all recent development, latest trends and futuristic the technological impact of uniquely specific industries.

Contact Details:Maximize Market Research Pvt. Ltd.Phone: US: +1 774 775 2163; APAC: +91-9607365656Email:[emailprotected]Website:www.maximizemarketresearch.com

Maximize Market Research provides B2B and B2C research on 12000 high growth emerging opportunities & technologies as well as threats to the companies across the Healthcare, Pharmaceuticals, Electronics & Communications, Internet of Things, Food and Beverages, Aerospace and Defense and other manufacturing sectors.

See the article here:
Neuroscience Market:Industry Analysis and Forecast 2021-2027| Key Players Doric Lenses . GE Healthcare , Siemens Healthineers , Laserglow Technologies...

Neuroscience

Neuroscientist Paxinos’ 21-year odyssey is over with publication of first novel – Neos Kosmos

Over a long and distinguished career in neuroscience, Prof George Paxinos has identified more areas of the brain than anyone else in history, he has also written 57 books on the subject. Now he has dipped into the waters of fiction with the publication of his first novel A River Divided.

It took him 21 years and countless revisions to publish the book, a process that was harder than anything he had attempted before.

The central idea came to me one night in 1999, of identical twins raised apart and I filled in the plot over the years, Paxinos told Neos Kosmos. The rest was sheer persistence as he set about writing and revising the book to his ultimate satisfaction.

The idea developed in the book so that the identical twins are cloned from the remains of a man found near Masada, the Jewish fortress near the Dead Sea that resisted a Roman siege to the death.

The remains are those of the biblical Jesus. The clone is accidentally divided into two identical embryos which are transferred to two host mothers. One grows up in Australia the other in completely different circumstances in South America. The twins meet again as adults confronting each other from very different positions.

The novel guided by the story grapples with important ethical and moral issues, with the environmental crisis at its heart. In the 1980s Paxinos was a key advocate for the founding the Light Rail Association to bring back the tram to Sydney and in 2015 he was the Australian Cyclists Party candidate in the New South Wales state elections.

The issue of our time today is the environment. I try to penetrate what Christ would have said today. In Christs time the issue was justice. We must not give the next generation, the burden of a damaged environment, Paxinos said.

READ MORE: George Paxinos launches new book: The Brain Atlas

If Christians get over the initial shock of the finding (and cloning) Christs remains, I think they will find it was a choice made from affection for Christ and the ideas he produced. I hope they will not find this idea disagreeable.

A book needs heart, soul and mind, the book has all three elements but it is also (about) reflection, conflict and internal debate. It grapples with some important issues.

The books title, A River Divided refers to the confluence of two very different rivers, the lighter coloured muddier colder Rio Solimes and the darker, warmer Rio Negro. The rivers which meet near the city Manaus and retain their individual character until they eventually blend 25km downstream to become the mighty Amazon River. Plans to dam a river in the region, draw the twins who are in opposite ends of the situation.

The action of the book runs through various settings from Israel, to Australia, the Vatican and South America and the author visited each place as part of his research in writing the novel.

When he wrote The Brain Atlas he put in 110 hours a week for several months in order to complete it.

I gave more to this than my scientific works, Paxinos said.

Literature is hard. I would not let my scientific books go (for publication) until I could not add anything more. I did not feel that way for this book and up until the last moment I felt I was improving the manuscript. A book must hang together with the right flow, expression and emotions, it must not be inappropriate.

His academic books are highly acclaimed in the field of neuroscience with his first one The Rat Brain in Stereotaxic Coordinates, as the most cited publication in neuroscience and was the third-most cited work in all of science for several decades.

In teaching undergraduates and post graduates over the years helped him to gauge what would work for readers of the novel- unlike his academic books, a novel should not be didactic or preach, the story and the characters guides the flow of the book.

Some key concepts of neuroscience to weave their way into the A River Divided: the role of our genetic endowment versus the influence of our environment in sculpting our character being one example.

Had the brain been smaller then we would not have had technology, had our brain been larger and better functioning then we would have solved many of the problems that affect us now. Unfortunately, the brain is just not the right size, Paxinos said.

I used my neuroscientist background to craft the characters. I visited the places reflected in the novel and received a lot of help from scientists. It is accurate and comprehensible scientifically to the point that a Greek kindergarten teacher diagnosed the symptoms of Temporal Lobe Glioma in one of her friends on the basis of the description of the symptoms in one of the characters in the novel.

READ MORE: Groundbreaking discovery in neuroscience by Greek researcher

He had tried to first get the book published in Australia but conveying what it was about with its complexity of themes was a problem. He took the manuscript to Greece in 2015 where Livanis Publications took it up and translated into the Greek under the title In His Image.

The publisher in Greece said: Dont tell me anything, just read me the last page.

The lady cried and I thought a publisher will normally only cry if the book does not sell, Paxinos joked.

Having seen the book in his native language, he obtained a better understanding of the emotions of the characters he had created and spent another six years improving the English version.

Every time I revised the book, I would make many corrections but each time they improved the book.

The persistence that is his trademark has paid off but Paxinos says his next novel should be titled How to write a novel in less than 25 years.

A River Divided by George Paxinos is published in Australia by Heads and Tales will be available from Mid-November in Booktopia and good book stores.

Read the original here:
Neuroscientist Paxinos' 21-year odyssey is over with publication of first novel - Neos Kosmos

Neuroscience

Xen by Neuvana: First-of-its-kind Vagus Nerve Stimulation Device Now Shipping to the United Kingdom and European Union – PRNewswire

Xen by Neuvana is a pocket-sized device that connects to your mobile phone through an app and sends a gentle electrical signal through patented earbuds to stimulate the vagus nerve in the ear. Invented by a leading cardiac surgeon and supported by science, Xen's innovative design targets the vagus nerve, the longest cranial nerve in the body, which acts as the information highway from the brain to most of the body's major organs. When stimulated, the vagus nerve activates the parasympathetic nervous system by signaling the brain to release calming neurotransmitters such as acetylcholine and norepinephrine. This natural chemical process can help the body feel calmer, more focused, increase mood, and achieve better sleep too.

"We have had an outpouring of interest from consumers outside of the U.S. wanting to try Xen and experience the health benefits users have shared that improve their day-to-day lifestyle," said Vince Manopoli, CEO of Neuvana. "We are excited to continue to expand the company's footprint to our friends overseas and deliver Xen into the hands of people who are looking for alternative ways to manage the health impact of stress, anxiety, and poor sleep "

Initially launched in the United States in 2019, Xen was specifically designed to meet the high standards of product safety testing and certification in order to bring the product to consumers overseas. It has earned the esteemed CE marked certification, which applies to products intended for the European market that have been tested and found to comply with each country's high safety requirements.

"With the safety of our customers always at the forefront, we continue to work diligently to meet the most stringent guidelines for our products according to each country's specific requirements," said Manopoli. "Furthermore, it's important to us that we do so without compromising the product's health benefits or diminishing the overall customer experience. Thanks to an incredible team of engineers and scientists behind our product, we have successfully accomplished just that."

Starting this week, consumers can preorder their Xen product starting at 444.70 EUR online at http://www.neuvanalife.com. The company will start shipping to all EU countries and the UK beginning November 15.

Science Behind Vagus Nerve Stimulation (VNS)

The vagus nerve controls part of the body's automatic responsesthe parasympathetic nervous system. The term "vagus" is named after the Latin word for "wandering," as it starts at the brain, and travels near the ear, and on to every major organ in the body. As a result, it controls a vast range of functions and communicates sensory information between the brain and the organs. The vagus nerve is crucial for activating the body's relaxation response and helping to regulate tension. Just like a muscle, when toned or strengthened regularly, the functions of the vagus nerve can be amplified and its response can help a person recover quicker from stressful events.

Backed by Research

Neuvana is considered a leader in neuroscience technology, specifically in the vagus nerve stimulation (VNS) category. As a company, its focus is centered around pairing neuroscience and technology to develop innovative products to better people's health and everyday lifestyle. As part of this process, Neuvana is involved in research surrounding VNS with the following institutions: Walter Reed National Military Medical Center, Air Force Research Laboratory (AFRL), Defense Advanced Research Projects Agency (DARPA), University of Maryland, Thomas Jefferson University Hospital, Defense Language Institute Foreign Language Center, among others.

About Neuvana LLC

Neuvana, LLC is a South Florida-based company at the intersection of wellness and technology, with a focus on Neuroscience. Founded in 2014 by Richard Cartledge, MD, an inventor and chief of cardiovascular surgery at Boca Raton Regional Hospital, the company is comprised of engineers, clinicians, experienced business professionals and a world-class scientific advisory board with a shared goal: to create a platform to make the wellness benefits of neuroscience safe, easy and accessible to everyone. In late 2019, Neuvana released its flagship product, Xen, which stimulates the vagus nerve system through patented earbuds to help reduce stress, boost sleep and improve focus. For more information about Neuvana, its board members and product details, visit http://www.neuvanalife.com.

Press Contact: Sarah Cooke, 5613156946

SOURCE Neuvana LLC

Read the original post:
Xen by Neuvana: First-of-its-kind Vagus Nerve Stimulation Device Now Shipping to the United Kingdom and European Union - PRNewswire

Neuroscience

Experts address the limitations of studying individual brains in cognitive neuroscience – News-Medical.Net

In a new paper, scientists suggest that efforts to understand human cognition should expand beyond the study of individual brains. They call on neuroscientists to incorporate evidence from social science disciplines to better understand how people think.

"Accumulating evidence indicates that memory, reasoning, decision-making and other higher-level functions take place across people," the researchers wrote in a review in the journal Frontiers in Systems Neuroscience. "Cognition extends into the physical world and the brains of others."

The co-authors neuroscientist Aron Barbey, a professor of psychology at the University of Illinois Urbana-Champaign; Richard Patterson, a professor emeritus of philosophy at Emory University; and Steven Sloman, a professor of cognitive, linguistic and psychological sciences at Brown University wanted to address the limitations of studying brains in isolation, out of the context in which they operate and stripped of the resources they rely on for optimal function.

In cognitive neuroscience, the standard approach is essentially to assume that knowledge is represented in the individual brain and transferred between individuals. But there are, we think, important cases where those assumptions begin to break down."

Aron Barbey, Neuroscientist and Professor of Psychology, University of Illinois Urbana-Champaign

Take, for instance, the fact that people often "outsource" the task of understanding or coming to conclusions about complex subject matter, using other people's expertise to guide their own decision-making.

"Most people will agree that smoking contributes to the incidence of lung cancer without necessarily understanding precisely how that occurs," Barbey said. "And when doctors diagnose and treat disease, they don't transfer all of their knowledge to their patients. Instead, patients rely on doctors to help them decide the best course of action.

"Without relying on experts in our community, our beliefs would become untethered from the social conventions and scientific evidence that are necessary to support them," he said. "It would become unclear, for example, whether 'smoking causes lung cancer,' bringing into question the truth of our beliefs, the motivation for our actions."

To understand the role that knowledge serves in human intelligence, the researchers wrote that it is necessary to look beyond the individual and to study the community.

"Cognition is, to a large extent, a group activity, not an individual one," Sloman said. "People depend on others for their reasoning, judgment and decision-making. Cognitive neuroscience is not able to shed light on this aspect of cognitive processing."

The limitations of individual knowledge and human dependence on others for understanding are the themes of "The Knowledge Illusion: Why We Never Think Alone," a book Sloman wrote with Phil Fernbach, a cognitive scientist and professor of marketing at the University of Colorado.

"The challenge for cognitive neuroscience becomes how to capture knowledge that does not reside in the individual brain but is outsourced to the community," Barbey said.

Neuroscientific methods such as functional MRI were designed to track activity in one brain at a time and have limited capacity for capturing the dynamics that occur when individuals interact in large communities, he said.

Some neuroscientists are trying to overcome this limitation. In a recent study, researchers placed two people face-to-face in a scanner and tracked their brain activity and eye movements while they interacted. Other teams use a technique called "hyperscanning," which allows the simultaneous recording of brain activity in people who are physically distant from each another but interacting online.

Such efforts have found evidence suggesting that the same brain regions are activated in people who are effectively communicating with one another or cooperating on a task, Barbey said. These studies are also showing how brains operate differently from one another, depending on the type of interaction and the context.

Several fields of research are ahead of neuroscience in understanding and embracing the collective, collaborative nature of knowledge, Patterson said. For example, "social epistemology" recognizes that knowledge is a social phenomenon that depends on community norms, a shared language and a reliable method for testing the trustworthiness of potential sources.

"Philosophers studying natural language also illustrate how knowledge relies on the community," Patterson said. "For example, according to 'externalism,' the meaning of words depends on how they are used and represented within a social context. Thus, the meaning of the word and its correct use depends on collected knowledge that extends beyond the individual."

To address these shortfalls, neuroscientists can look to other social science fields, Barbey said.

"We need to incorporate not only neuroscience evidence, but also evidence from social psychology, social anthropology and other disciplines that are better positioned to study the community of knowledge," he said

Source:

Journal reference:

Sloman, S. A., et al. (2021) Cognitive Neuroscience Meets the Community of Knowledge. Frontiers in Systems Neuroscience. doi.org/10.3389/fnsys.2021.675127.

Visit link:
Experts address the limitations of studying individual brains in cognitive neuroscience - News-Medical.Net

Neuroscience

Gladstone Neuroscience Researcher Elected to the National Academy of Medicine – Yahoo Finance

Lennart Mucke is recognized for his pioneering discoveries in research on Alzheimer's disease and related disorders

SAN FRANCISCO, Oct. 19, 2021 /PRNewswire/ -- Lennart Mucke, MD, founding director of the Gladstone Institute of Neurological Disease and senior investigator at Gladstone Institutes, has been elected to the National Academy of Medicine (NAM). Election to the Academy is considered one of the highest honors in the fields of health and medicine and recognizes individuals who have demonstrated outstanding professional achievement and commitment to service.

Lennart Mucke is recognized by the National Academy of Medicine for his leading role in defining molecular and pathophysiological mechanisms by which Alzheimers disease causes synaptic failure, neural network dysfunctions, and cognitive decline. Photo: Michael Short/Gladstone Institutes

The prestigious recognition is a testament to Mucke's long track record of contributions to disease-focused neuroscience, and particularly to Alzheimer's disease and other conditions that rob people of their abilities to control and enjoy their lives.

Alzheimer's disease is a complicated and multifactorial condition that affects more than 50 million people worldwide, including 6 million in the United States, causing many abnormalities in the brain. Mucke has played a leading role in deciphering which of these abnormalities actually contribute to cognitive declineand therefore merit therapeutic interventionand which may be "red herrings," for example changes that look ominous under the microscope but do not actually cause loss of memory or other key symptoms of the disease.

In doing so, Mucke has debunked several dogmas and helped focus the field's attention on molecular and cellular processes that truly matter in regard to brain functions and the main symptoms that impair the lives of patients and their caretakers. His discoveries include the demonstration that key proteins implicated in Alzheimer's diseaseincluding amyloid-beta, apolipoprotein E4 (apoE4), and taucan cause brain dysfunctions independent of plaques and tangles, which are pathological hallmarks of the disease.

Mucke also discovered that tau regulates the activity of neurons, and that reducing the levels of this protein in the brain blocks abnormal neuronal activities in experimental models of diseases as diverse as Alzheimer's, epilepsy, and autism. Several of his scientific discoveries are being translated into novel therapeutics for these and related conditions by his team and others in academia and the biopharmaceutical industry.

Story continues

"I am most grateful to the outstanding investigators who nominated me and to the many NAM members who supported me with their vote," says Mucke, who is also the Joseph B. Martin Distinguished Professor of Neuroscience and a professor of neurology at UC San Francisco. "Many of my former and current coworkers contributed to this achievement, and we all share this honor together. I greatly appreciate what the NAM stands for and will do whatever I can to support its mission."

A Global and Multipronged Approach to Overcoming Alzheimer's Disease

Despite a significant investment in research, potential therapies for Alzheimer's disease have been slow to arrive, most likely because of the complexity and multifactorial nature of the disease.

"The path toward generating therapeutics that are efficacious and safe when given to millions of people for many years is always challenging," Mucke notes. "This process is made even more difficult in the case of Alzheimer's disease because it affects the elderly, who often suffer from other aging-related conditions requiring treatments that might adversely interact with novel therapeutics for Alzheimer's."

To address this complexity, Mucke is leading efforts at Gladstone to investigate how multiple genetic and non-genetic factors come together to promote the disease. This multipronged approach is helping to diversify the drug development portfolio for Alzheimer's disease. Mucke and his colleagues are also using similar approaches to develop better therapies for other diseases that affect the nervous system, including Parkinson's disease, frontotemporal dementia, epilepsy, and autism.

"My hope is that our comprehensive strategy will improve treatment options for several common, devastating, and incurable diseases," says Mucke. "To be successful in this quest, we must continue to nurture interactions between basic scientists and clinicians, as well as between academia and industry."

To ensure an even broader, global impact of his experience and expertise, Mucke has served as an advisor on innovative neurodegenerative disease-focused initiatives to the governments of the United States, Germany, and the United Kingdom, and to several major pharmaceutical companies.

He has also mentored over 60 graduate students and postdoctoral scholars, many of whom are now leading their own labs throughout the country and continuing to contribute to the field of neuroscience research.

"I have a great passion for mentorship and like to tailor my approaches to the particular needs and potential of each individual," he says. "I believe that my colleagues and I have created an adventuresome team spirit and uncompromising standard of excellence that is ideal for training in disease-focused neuroscience."

Mucke has been at Gladstone since 1996, but can trace his interest in neuroscience and medicine back to his teenage years.

"I developed a great interest in psychiatry, neurology, and neuroscience when I was in high school and to this day can't think of anything more fascinating and rewarding than to discover how the brain works and how to preserve the fragile structures that harbor the very essence of who we are," he says.

He is a graduate of the Georg-August University and the Max Planck Institute for Biophysical Chemistry (Neurobiology) in Gttingen, Germany. He trained in internal medicine at the Cleveland Clinic, in neurology at Massachusetts General Hospital and Harvard Medical School, and in neuroimmunology and neurovirology at The Scripps Research Institute. He is also a member of the American Neurological Association and the Association of American Physicians.

Mucke's election was announced on October 18, 2021, by the NAM, which is part of the congressionally chartered National Academy of Sciencesprivate, nonprofit institutions that provide objective advice on matters of science, technology, and health. He joins six fellow NAM members from Gladstone Institutes: Jennifer Doudna, PhD, senior investigator; Warner Greene, MD, PhD, senior investigator and director of the Michael Hulton Center for HIV Cure Research; Robert W. Mahley, MD, PhD, senior investigator, president emeritus, and Gladstone founder; Deepak Srivastava, MD, senior investigator and current president of Gladstone; R. Sanders Williams, MD, former Gladstone president; and Shinya Yamanaka, MD, PhD, senior investigator.

About Gladstone Institutes

To ensure our work does the greatest good, Gladstone Institutes focuses on conditions with profound medical, economic, and social impactunsolved diseases. Gladstone is an independent, nonprofit life science research organization that uses visionary science and technology to overcome disease. It has an academic affiliation with the University of California, San Francisco.

Media Contact: Julie Langelier | Associate Director, Communications | julie.langelier@gladstone.org | 415.734.5000 1650 Owens Street, San Francisco, CA 94158 | gladstone.org

Gladstone Institutes logo (PRNewsfoto/Gladstone Institutes)

Cision

View original content to download multimedia:https://www.prnewswire.com/news-releases/gladstone-neuroscience-researcher-elected-to-the-national-academy-of-medicine-301403807.html

SOURCE Gladstone Institutes

Go here to see the original:
Gladstone Neuroscience Researcher Elected to the National Academy of Medicine - Yahoo Finance